Douglas E. Onsi - 31 Jan 2022 Form 4 Insider Report for LEAP THERAPEUTICS, INC. (LPTX)

Reporting relationship: CEO,CFO,Pres.,GC,Treas.,&Sec., Director, 10%+ Owner
Issuer ticker: LPTX
Reported as of: 31 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Feb 2022, 20:47:31 UTC
Prior SEC filing: 28 May 2021
Next SEC filing: 02 Sep 2022
Source filing: View source filing
Reporting owner signature: /s/ Douglas E. Onsi

Key filing fact

Douglas E. Onsi filed Form 4 for LEAP THERAPEUTICS, INC. (LPTX) on 02 Feb 2022.

Key facts

This page summarizes Douglas E. Onsi's Form 4 filing for LEAP THERAPEUTICS, INC. (LPTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Feb 2022, 20:47.

Change

Previous filing in this sequence was filed on 28 May 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LPTX transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +325,000
Change %
Price: $0.000000
Shares after: 325,000
Date: 31 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 325,000
Exercise price: $0.000000
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Restricted Stock Units were awarded pursuant to Leap's 2016 Equity Incentive Plan for no consideration. Restricted Stock Units will be settled in common stock.

Footnote F2

The Restricted Stock Units will cliff vest and be settled after three years of continuous service or upon a change of control of Leap, whichever is earlier.